Ovarian cancer
RecruitingStudy of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer
Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer
- Disease:Ovarian cancer
- Substances:BevacizumabTrastuzumab Deruxtecan
Germany- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Daiichi Sankyo Inc.











